Celcuity reported a narrower-than-expected Q2 loss, beating analyst consensus. Despite positive clinical and regulatory milestones for gedatolisib (REVTORPYK), analysts from Needham and Stifel lowered their price targets, likely due to the delayed shipping timeline for REVTORPYK to late Q3 2026.
Celcuity (CELC) announced a Q2 loss that was better than analyst expectations, alongside significant clinical and regulatory progress for its drug gedatolisib (REVTORPYK). The CEO highlighted FDA approval, positive study results, and NCCN guideline recommendations, positioning the drug to address a substantial unmet need. However, the crucial detail for investors is the updated timeline for REVTORPYK shipping, now projected for late Q3 2026. This delay, despite the positive clinical news, appears to be the primary driver behind analysts from Needham and Stifel lowering their price targets. While the stock saw a slight pre-market rise, the long-term implications of a delayed product launch could temper investor enthusiasm, creating a short-term opportunity for traders to assess if the market has fully priced in the extended wait for revenue generation from REVTORPYK.